Abstract CT103: Final results for OptimalTTF-1: Optimizing Tumor Treating Fields with targeted skull remodeling surgery for first recurrence glioblastoma: Phase 1 trial

Nikola Mikic, Anders Rosendal Korshoej, Slávka Lukacova, Jens Christian Hedemann Sørensen, Frederik Lundgaard Hansen, Axel Thielscher, Søren Cortnum, Trine Lignell Guldberg, Yasmin Lassen-Ramshad, Christian Rahbek, Kare Eg Severinsen, Gorm von Oettingen

Research output: Contribution to journalConference abstract in journalResearchpeer-review

Abstract

We present a clinical open label, phase-1 trial (OptimalTTF-1, NCT02893137), which aims to test a novel treatment for first recurrence glioblastoma (rGBM). The aim of the treatment is to optimize the electric field generated by Tumor Treating Fields (TTFields) with targeted and individualized skull-remodeling surgery (SR-surgery). Selectively placed burrholes reduces the electric resistance created by the bone and thus improves the electric field focally. Preclinical research has indicated this conclusion. The final analysis examined the toxicity and efficacy of this combined intervention in addition to best practice chemotherapy.
Original languageEnglish
Article numberCT103
JournalCancer Research
Volume80
Issue number16, suppl.
ISSN0008-5472
DOIs
Publication statusPublished - 2020
EventAACR Annual Meeting 2020 - Online, Philadelphia, United States
Duration: 27 Apr 202028 Apr 2020

Conference

ConferenceAACR Annual Meeting 2020
LocationOnline
CountryUnited States
CityPhiladelphia
Period27/04/202028/04/2020

Fingerprint Dive into the research topics of 'Abstract CT103: Final results for OptimalTTF-1: Optimizing Tumor Treating Fields with targeted skull remodeling surgery for first recurrence glioblastoma: Phase 1 trial'. Together they form a unique fingerprint.

Cite this